Towards a new generation of digital diabetes solutions: Artificial pancreas for patients with continuous monitoring devices and smart pen insulin. (2022 – 2025). Reference: CPP2021-008659. Funded by MCINN – 656.441,06€. P.I. Josep Vehí. Other participants: Social Diabetes.
SUMMARY:
The overall goal of the project is to provide patients with DT1 on multi-dose insulin therapy using smartpens with the same benefits as patients with automated insulin pump systems (artificial pancreas). This is intended to enable them to lead a daily life as close as possible to that of a healthy person, reducing the burden associated with daily blood glucose management.
SocialDiabetes is a comprehensive digital platform consisting of a mobile application and a web platform, which has been developed by patients and doctors, which allows access to personalized services and content for the care of the diabetic patient in an ergonomic, accessible and efficient way from anywhere, generating a more efficient care ecosystem that revolves around an active, autonomous and under control patient.
CPP2100-008659/ founded by MCIN/AEI/10.13039/501100011033 and by the European Union-NextGenerationEU/PRTR
TEAM:
MICELAB:
|
Research leads:
|
Research Team:
|
SOCIAL DIABETES:
- Victor Bautista Bermúdez
- José María Ferré Carbonell
- Ana Hernández Janes
- Adrián Villamayor Sánchez
- Mercedes Salido Rojo
SUMMARY:
- To clinically validate a control algorithm for blood glucose control for people with T1D that includes correction insulin boluses and rescue carbohydrate recommendations.
- To translate the technical results into a commercial platform, reaching a level 9 Technology Readiness Level (TRL).
